Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Zachary J. Roberts"'
Autor:
Anna E. Mullins, Ankit Parekh, Korey Kam, Bresne Castillo, Zachary J. Roberts, Ahmad Fakhoury, Daphne I. Valencia, Reagan Schoenholz, Thomas M. Tolbert, Jason Z. Bronstein, Anne M. Mooney, Omar E. Burschtin, David M. Rapoport, Indu Ayappa, Andrew W. Varga
Publikováno v:
Frontiers in Physiology, Vol 12 (2021)
Obstructive sleep apnea (OSA) is considered to impair memory processing and increase the expression of amyloid-β (Aβ) and risk for Alzheimer’s disease (AD). Given the evidence that slow-wave sleep (SWS) is important in both memory and Aβ metabol
Externí odkaz:
https://doaj.org/article/b00fd74d7d704889a1ecdf5838c87716
Autor:
Jacob Engellau, Leanne Seeger, Robert Grimer, Robert Henshaw, Hans Gelderblom, Edwin Choy, Sant Chawla, Peter Reichardt, Michael O’Neal, Amy Feng, Ira Jacobs, Zachary J. Roberts, Ada Braun, Bruce A. Bach
Publikováno v:
World Journal of Surgical Oncology, Vol 16, Iss 1, Pp 1-9 (2018)
Abstract Background Denosumab has been shown to reduce tumor size and progression, reform mineralized bone, and increase intralesional bone density in patients with giant cell tumor of bone (GCTB); however, radiologic assessment of tumors in bone is
Externí odkaz:
https://doaj.org/article/68795b5d42b14e8ebc8008677013379f
Autor:
Zachary J. Roberts, Alessandro Fichera
Publikováno v:
Updates in Surgery. 75:451-454
Autor:
Martine Thomas, Gray Kueberuwa, John S. Bridgeman, Natalia Kirillova, Zachary J. Roberts, Ryan D. Guest, Yizhou Jiang, Paul Lorigan, Manon Pillai, Robert E. Hawkins, Fiona C Thistlethwaite
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTumor infiltrating lymphocyte (TIL) products made from tumor digests showed a high overall response rate (ORR; 67%) and complete response (CR) rate (19%) and a safety profile consistent with lymphodepletion and high-dose interleukin (IL)-2
Publikováno v:
Bone Marrow Transplantation
Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
Autor:
Scott J. Rodig, Zachary J. Roberts, William Y. Go, John J. Rossi, Caron A. Jacobson, Stuart A. Sievers, Adrian Bot, Mikel Lipschitz, Pei-Hsuan Chen, Jason L. Weirather, F. Stephen Hodi, Kyle Wright, Philippe Armand
Publikováno v:
JCI Insight
Mechanisms of chimeric antigen receptor (CAR) T cell–mediated antitumor immunity and toxicity remain poorly characterized because few studies examine the intact tumor microenvironment (TME) following CAR T cell infusion. Axicabtagene ciloleucel is
Autor:
Rubén Alvarez-Rodríguez, Donald P. Lawrence, Paul D. Robbins, Pippa Corrie, Audrey Kennedy, John Le Gall, Yizhou Jiang, Zachary J. Roberts, Geoffrey T. Gibney, Omid Hamid, Brian R. Gastman, Amod A. Sarnaik, Gregory A. Daniels, Sajeve Samuel Thomas, Bartosz Chmielowski, Evidio Domingo-Musibay, Jeff Aycock, Robert E. Hawkins
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPatients with advanced cutaneous melanoma and persistent disease after checkpoint inhibitor therapy have poor outcomes and limited treatment options, highlighting a significant unmet medical need.1 Autologous TIL cell therapies have shown p
Autor:
John S. Bridgeman, Zachary J. Roberts, Paul Lorigan, Natalia Kirillova, Ryan D. Guest, Robert E. Hawkins, Gray Kueberuwa, Manon Pillai, Martine Thomas, Fiona C Thistlethwaite, Yizhou Jiang
Publikováno v:
Annals of Oncology. 32:S882
Autor:
Ryan S. Guest, Yizhou Jiang, Natalia Kirilova, Manon Pillai, John S. Bridgeman, Martine Thomas, Zachary J. Roberts, Robert E. Hawkins, Paul Lorigan, Fiona C Thistlethwaite, Gray Kueberuwa
Publikováno v:
Cancer Research. 81:LB150-LB150
Introduction: A minority of patients (pts) with advanced melanoma achieve long-term survival with immunotherapy and those who relapse following immune checkpoint inhibition (ICI) or BRAFi have limited treatment options. The intrinsic anti-tumor activ
Autor:
John M. Rossi, Jennifer Lee, Jinghui Dong, Zachary J. Roberts, Alex F. Herrera, Mauro P. Avanzi, Jason R. Westin, Jennifer Sun, Judy Seng, David B. Miklos, Frederick L. Locke, Caron A. Jacobson, Remus Vezan
Publikováno v:
Cancer Research. 80:CT055-CT055
Background: Axi-cel is a US and EU-approved autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for the treatment of adult relapsed/refractory LBCL after ≥ 2 prior lines of therapy. In ZUMA-1, the objective response rate (ORR) was 8